• Mohammed A Alamin, Abdulrahman Al-Mashdali, Dawoud I Al Kindi, Elkhansa A Elshaikh, and Fahmi Othman.
• Hamad General Hospital, Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
• Medicine (Baltimore). 2022 Oct 21; 101 (42): e28243e28243.

RationaleEptifibatide is an antiplatelet agent used in the medical management of acute coronary syndrome. Although multiple studies did not reveal a significant association between eptifibatide and the development of thrombocytopenia, recent case reports brought attention to this relatively rare side effect.Patient ConcernsWe report a 61 years old male with acute coronary syndrome who underwent primary coronary intervention.Diagnosis And InterventionThe patient developed acute profound thrombocytopenia following eptifibatide administration. Following prompt offending drug discontinuation, the platelet counts recovered, without clinical sequelae or the need for platelet transfusion. Dual antiplatelet therapy with aspirin and clopidogrel was resumed after platelet count normalization.OutcomesThe patient had a normal platelet count and no bleeding events on follow-up after three months upon discharge.ConclusionEptifibatide, a glycoprotein IIa/IIIb inhibitor used in the management of acute coronary syndrome, can induce acute, profound thrombocytopenia that can have significant morbidity in patients. This case highlights this relatively rare side effect and the importance of monitoring blood counts and observing for any signs of bleeding or thrombosis that might occur in such patients.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

19 keywords...

hide…